Superior Engraftment and Survival and Less GVHD in NOD-SCID Il2rgnull (NSG) Mice Receiving Intrabone Compared With Iv Transplants of Human T-Cell Replete G-CSF Mobilized Peripheral Blood Stem Cells  by Pantin, J.M. et al.
S166 Oral PresentationsGVL. We report a completed phase I/II study of bortezomib-based
GVHD prophylaxis in 1-2 locus HLA-mismatched (A, B, C, DRB1,
DQB1) unrelated donor (MMUD) RIC HSCT. Phase I data docu-
mentedMTDand safety of a regimen of bortezomib (1.3mg/m2; day
11, 14, 17), methotrexate and tacrolimus.
Patients: 45 patients with a median age of 59 years (range, 27-72)
were enrolled. Donor mismatch: HLA-A (12), B (10), C (14),
DRB1 (2), DQB1 (2), B1C (4), DRB11DQB1 (1); 1-antigen (28),
2-antigen (3), 1-allele (11), 2-allele (1), 1-antigen11-allele (2). Dis-
ease: AML (14), NHL (11), CLL/PLL (8), HD (4), MDS (4), ALL
(2), MPD (2). 8 had prior transplants. Median follow-up in survivors
was 12.5 months (range, 3.3-37.2).
Results: Median time to PMN and platelet engraftment was 13
(range, 6-29) and 20 days (range, 13-27) respectively; notably 23 pa-
tients had no PMN nadir and 21 had no platelet nadir. 1 patient failed
to engraft and 4 did not sustain graft chimerism $ 70% through day
1100 in the absence of disease relapse/progression. Median day 130
and 1100 chimerism was 97% and 99% respectively. 15 patients re-
lapsed. 9 patients died: relapse-6; bacterial infection-2; CNS hemor-
rhage-1. 11 had grade 2-4 acute GVHD (gr-2:8; gr-3:3). 16 had
chronic GVHD requiring systemic therapy. No neuropathy flare or
colonic necrosis was noted. Adjusted for competing risks, 6-month
cumulative incidence of grade 2-4 acute GVHD is 24% (95% CI,
13-38); and 1-year cumulative incidence of NRM is 7% (95% CI,
2-18), relapse is 32% (95% CI, 18-47), and chronic GVHD is 39%
(95% CI, 23-55). 1-year progression-free survival is 61% (95% CI,
44-74), and overall survival is 77% (95% CI, 60-87). Preliminary
data suggest improved T-cell reconstitution with this regimen.
Conclusion: Bortezomib-based therapy enabled GVHD control af-
ter MMUD HSCT without impaired immunologic reconstitution,
relapse, orNRM. 1-year survival is encouraging. Proteasome-inhibi-
tion should be evaluated in a randomized GVHD prevention trial.39
STATINS SYNERGIZE WITH CYCLOSPORINE IN INHIBITING MITOCHON-
DRIAL FUNCTION IN ACTIVATED T CELLS
Margineantu, D.H.1, Hockenbery, D.1,2, Martin, P.J.1,2, Storb, R.1,2,
Rotta, M.1, Mielcarek, M.1,2 1Fred Hutchinson Cancer Research Center,
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In a large retrospective analysis of outcomes among 567 recipients
of HLA-identical hematopoietic cell transplantation (HCT), we
found that prior treatment of donors with statins, a class of drugs
with cholesterol-lowering and immune-modulating effects, was asso-
ciated with profound protection against severe acute GVHD (Rotta et
al., Blood. 2010;115:1288). The protective effect was restricted to re-
cipients given cyclosporine (CSP)-based postgrafting immunosup-
pression and not observed among those given tacrolimus (TAC).
Based on the unexpected effect-association between statins and
CSP, we hypothesized that CSP and statins synergize in inducing
T cell hyporesponsiveness at the level of the mitochondrial mem-
brane by interacting with a number of cyclophilins, including cyclo-
philin D. To mimic the clinical HCT setting where donors are
treated with statins and recipients are given immunosuppressive
therapy with either CSP orTAC, wemeasured the bioenergeticmet-
abolic status (mitochondrial function) of T cells obtained from dogs
that were treated with statins in vivo as a function of activation ex vivo
in the presence of CSP or TAC. Specifically, dogs (n 5 3) were
treated with atorvastatin (2 mg/kg/day) and, after 3 weeks of statin
treatment, peripheral blood T cells were purified and activated
with concanavalin A (conA) in the presence of suboptimal concentra-
tions of either CSP (30 ng/mL) or TAC (0.1 ng/mL). Mitochondrial
function was then evaluated by serial real-time measurements of the
oxygen consumption rate (OCR) as an indicator of oxidative phos-
phorylation by using the Seahorse XF24 Extracellular Flux Analyzer.
In the presence of CSP, T cells from dogs treated in vivowith ator-
vastatin (n 5 3), total oxygen consumption during the first 5 hours
after conA-activation was reduced by 41% (p 5 0.12), 70% (p 5
0.005) and 100% (p 5 0.008), respectively, compared to T cells ac-
tivated in the absence of CSP. This statin-induced reduction inOCR
was not observed when in vivo statin-exposed T cells were activated
in the presence of TAC. Neither CSP nor TAC significantly sup-
pressed OCR in control T cells obtained from dogs that were nottreated with atorvastatin (n5 3). In summary, these findings support
our hypothesis that statins and CSP have synergistic inhibitory ef-
fects onmitochondrial function in activatedT cells, and they provide
a first step toward defining the key mechanisms of statin-mediated
protection against GVHD.40
DONOR Th17 AND Th1 CONTRIBUTE TO CHRONIC GRAFT-VERSUS-HOST
DISEASE
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Chronic graft-versus-host disease (cGVHD) remains a major cause
of late death and morbidity after allogeneic hematopoietic cell trans-
plantation, and the treatment of cGVHD remains challenging. To in-
vestigate the roles of Th17 cells and other Th subsets (Th1 and Th2)
in cGVHD, we first assessed the kinetics of Th cytokines in the
B10.D2 (H-2d)/ BALB/c (H-2d) model of cGVHD. In the early
phase (day 14) of post bone marrow transplant (BMT), donor T cells
produced significantly less IL-17 in the peripheral lymph nodes
(PLNs) of recipients in allogeneic BMT than in syngeneic BMT
(1.6860.09% vs. 4.3060.53%, p \ 0.01), while in the late phase
(day 28) donor T cells that produced IL-17 were increased signifi-
cantly in allogeneic recipients, compared with syngeneic controls
(7.7660.27% vs. 1.6160.16%, p\ 0.005). Next, we evaluated the
role of Th17 on cGVHD using IL-17-deficient mice on a B10.D2
background as donor mice. Upon transfer of IL-172/2 donor T cells,
skin cGVHDwas significantly ameliorated, as compared to recipients
of wild-type (WT) T cells (p 5 0.02). Histopathological examination
of the skin showed significantly reduced cGVHD pathology in recip-
ients of IL-172/2 donors (3.1761.09 vs. 8.5060.84, p5 0.006). Flow
cytometry analysis of the PLNs in the early phase (day 14) showed no
differences in Th1, Th2, and Tregs, while recipients of IL-172/2 had
significantly fewer Th1 (p\ 0.05) and Th17/Th1 (p\ 0.01) cells on
day 35. Furthermore, BMT from IFN-g2/2 B10.D2 donors signifi-
cantly improved the clinical cGVHD score, compared with WT do-
nors (p \ 0.05). Interestingly, in the early phase (day 14) of post
BMT, IFN-g2/2 donor T cells produced significantly more IL-17
in the PLNs than WT donor (4.4260.65% vs. 1.7160.27%, p \
0.01), while in the late phase (day 35), IFN-g2/2 donor T cells that
produced IL-17were decreased. Finally, we demonstrated that the ad-
ministration of ATRA or Am80, significantly decreased skin fibrosis
and alopecia, a dominant feature of cutaneous cGVHD. Flow cytom-
etry analysis of the PLNs on day 16 showed significant reductions in
Th1 and Th17 in Am80-treated recipients, as compared to controls.
Taken together, Th17, especially in the late-chronic phase, and Th1
contribute to the development of cGVHD by promoting the produc-
tion of proinflammatory cytokines. Targeting Th17 and Th1 may be
a promising strategy for preventing and treating cGVHD.41
SUPERIOR ENGRAFTMENT AND SURVIVAL AND LESS GVHD IN NOD-SCID
IL2RGNULL (NSG) MICE RECEIVING INTRABONE COMPARED WITH
IV TRANSPLANTS OF HUMAN T-CELL REPLETE G-CSF MOBILIZED
PERIPHERAL BLOOD STEM CELLS
Pantin, J.M.1, Tian, X.2, Keyvanfar, K.1, Zerfas, P.3, Eckhaus, M.3,
Childs, R.W.1 1National Heart, Lung, and Blood Institute, National
Institutes of Health, Bethesda, MD; 2National Heart, Lung, and Blood
Institute, National Institutes of Health, Bethesda, MD; 3National
Institutes of Health, Bethesda, MD
Background: Direct intrabone (IB) transplantation has been sug-
gested as a method to improve hematopoietic engraftment. An addi-
tional benefit may be an abrogation of graft versus host disease
(GVHD). In mouse models, IB injection of allogeneic splenocytes
prevents murine GVHD attributable to the immunosuppressive ef-
fect of the bone marrow stromal environment. The NSG mouse
Table 1. Outcome Following IV versus IB Xeno-transplantion
Group: IV IB XRT Control Untreated Control P (comparing IV vs. IB)
Median Survival (days) 22 >42 >42 >42 <0.0001
% Surviving at 6 weeks 24% (7/29) 83% (25/30) 100% (10/10) 100% (5/5) <0.0001
Median Hgb at 3 weeks (g/dL) 10.5 (n511) 10.8 (n520) 11.2 (n55) 11.3 (n55) 0.23
Median WBC at 3 weeks (K/uL) 1.46 2.65 1.02 1.16 0.025
Median Plt at 3 weeks (K/uL) 871 1080 930 1443 0.23
Median Human leukocytes (cells/ul) at 3 weeks 67 36 NA NA 0.38
Median % weight change at 3 weeks –13.6% (n516) –6.1% (n530) –5.1% (n510) 0.3% (n55) 0.03
Median Hgb at 6 weeks (g/dL) 9.1 (n57) 10 (n519) 13.1 (n55) 12.7 (n55) 0.12
Median WBC at 6 weeks (K/uL) 0.4 6.78 2.92 2.42 <0.0001
Median Plt at 6 weeks (K/uL) 84 729 986 1270 0.009
Median Human leukocytes (cells/ul) at 6 weeks 178 1005 NA NA 0.0003
Median % weight change at 6 weeks –11.1% (n57) –8.7% (n524) –2.8% (n510) 2.5% (n55) 0.7
Oral Presentations S167strain is an exceptional model for studying xeno-engraftment of hu-
man lympho-hematopoietic cells. We compared survival following
tail-vein (IV) vs. intrafemoral (IB) xeno-transplantation of T-cell
replete G-CSF mobilized human peripheral blood stem cells (G-
PBMNC) into NSG mice.
Methods:NSGmice underwent irradiation with 250 cGy followed 6
hours later by transplantation of 5x106 G-PBMNCs given either IV
(200 mL) or IB (5 mL) under isoflurane anesthesia. Paired mice (IV
vs. IB)were transplantedwith cells froma singledonor.Miceuntreated
or irradiated with 250 cGy that did not receive human cells served as
controls. Following transplantation, mice were weighed weekly and
were phlebotomized tomeasure complete blood counts and to quanti-
tate the % of engrafting human cells by FACS over the 6 week study
period. Necropsy was performed on mice from each group.
Results: Engraftment of human leukocytes was detectable in both
the IB and IV transplant recipients.Median survival was significantly
shorter in IV transplanted mice (22 days) compared to IB trans-
planted mice, where median survival was not reached at 6 weeks (p
\ 0.0001). IV recipients manifested more severe xeno-GVHD
symptoms than IB transplanted mice, losing significantly more
weight and becoming pancytopenic with bone marrows showing se-
vere hypo-cellularity which likely occurred as the consequence of
a graft-versus-murine hematopoiesis effect. In contrast, recipients
of IB transplanted cells did not develop pancytopenia despite having
significantly higher levels of engrafted human cells.
Conclusions: IB xeno-transplantation of humanG-PBMNCs results
in higher degrees of human leukocyte engraftment than IV transplan-
tation while simultaneously protecting the host fromGVHD. In con-
trast, recipients of IV transplantsweremore likely to loseweight and to
develop pancytopenia and marrow aplasia which significantly short-
ened survival compared to IB transplanted mice. These data suggest
the IB route of transplantation should be further studied as a method
to overcome GVHD associated with HLA disparity.42
A THREE BIOMARKER PANEL AT DAYS 7 AND 14 CAN PREDICT DEVEL-
OPMENT OF GRADE II-IV ACUTE GRAFT-VERSUS-HOST DISEASE
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We have previously identified five biomarker proteins that have
diagnostic and prognostic value for acute graft-versus-host disease
(GVHD) (Blood 113:273-278, Sci Transl Med 2:50-57). To deter-
mine whether biomarkers can predict GVHD before the appearance
of clinical symptoms, we measured the three most informative bio-
markers (IL2Ra, TNFR1, elafin) by sequential ELISA in patient
samples prospectively obtained prior to conditioning (pre-HCT),
on day17, and day114 after hematopoietic cell transplant (HCT)
from 513 unrelated (URD) HCT patients. We randomly divided
the patients into training (N 5 342) and validation (N 5 171) data
sets that were balanced for (i) full intensity conditioning, (ii) earlyonset of grade II-IV GVHD (\ day121), and (iii) HCT performed
after 2005. We used the training data set to simulate biomarker
values for a hypothetical 50,000 patients using the following assump-
tions: (1) the incidence of GVHD by day 100 is 55%; (2) the median
day of GVHD onset after full intensity URD HCT is day 21, with
10% developing GVHD prior to day17, and 3% after day156.
We used logistic regression to assign each of the 50,000 patients to
low risk and high risk of developing grade II-IV GVHD based
upon the biomarker levels pre-HCT and at day17. We measured
all three biomarkers again in samples taken at day114 in all patients
whowere categorized as low risk and who did not developGVHDby
day114. We determined with another logistic regression model
which low risk patients had now moved to the high risk category.
In the training data set, the combination of these two analyses cor-
rectly predicted the continued absence of grade II-IV GVHD (i.e.
specificity) in 77% (95% CI: 71%-83%) and correctly predicted
the eventual development of GVHD (i.e. sensitivity) in 50% (95%
CI: 42%-58%) of patients. In the validation data set, these tests
gave a specificity of 75% (95% CI: 67%-83%) and a sensitivity of
57% (95% CI: 44%-69%), (Table 1, first row).
Table 1. Sensitivity and Specificity Corresponding to Various
Values of Predicted Probability at Days +7 and +14 Applied to
Validation Data Set
Combined Specificity Combined Sensitivity Correct Prediction of
for both cutpoints for both cutpoints GVHD by Day 5675% 57% 65%
74% 48% 60%
73% 49% 60%
71% 58% 64%
70% 57% 63%The median time between a high risk determination and onset of
grade II-IV GVHD was 14 days. These cutpoints also led to the
greatest correct prediction of GVHD facilitating the design of a trial
to test preemptive treatment of GVHD using these panels. In con-
clusion, measurement of a three-biomarker panel pre-HCT, at
day17, and day114 predicts grade II-IVGVHDwith good specific-
ity (75%) and fair sensitivity (57%).43
INHIBITION OF PROTEIN GERANYLGERANYLATION AND FARNESYLA-
TION PROTECTS AGAINST GvHD
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Wehave previously shown that blocking the L-mevalonate pathway
by statins reduces acute graft-versus-host disease (GvHD) in the mu-
rine bone marrow transplanation (BMT) model (Zeiser R et al. Blood
